Tradestie Institutional Equity Comparison Engine

ACHV vs ICCC โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ICCC Overall Edge

ICCC Captures Institutional Edge (2โ€“2 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Immucell Corp (ICCC) driven by superior Growth & Margin, Momentum & Technical while ACHV counters with relative strength in Valuation, Options & Structure. Fundamentally, ACHV trades at 35.3x Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus ICCC at N/M Forward P/E and 15.2% operating margin (+11.5% YoY). In options structure, ACHV sits in BREAKOUT (23rd %ile IV; Dealer Gamma Walls on Pro) against ICCC sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner ACHV
ACHV 35.3x vs ICCC N/M Fwd P/E
Growth & Margin Winner ICCC
Op Margin 0.0% vs 15.2% ยท YoY +0.0% vs +11.5%
Momentum & Technical Winner ICCC
1Y +43.0% vs +88.8% ยท 52W Pos 69% vs 91%
Options & Structure Winner ACHV
BREAKOUT (23rd %ile IV) vs UNCLASSIFIED (N/A IV)
ACHV NASDAQ
Achieve Life Sciences, Inc.
In Vitro & In Vivo Diagnostic Substances
$6.78
+0.89% 1D
Market Cap $692.8M
1M Return -8.5%
1Y Return +43.04%
Forward P/E 35.3x
Unified AI Score
56.6 / 100 HOLD
Tech 66.0 Fund 58.0 Flow 57.0 Mom 58.9
ICCC NASDAQ
Immucell Corp
In Vitro & In Vivo Diagnostic Substances
$11.42
+6.23% 1D
Market Cap $97.7M
1M Return +6.23%
1Y Return +88.76%
Forward P/E N/M
Unified AI Score
43.8 / 100 HOLD
Tech 15.0 Fund 48.0 Flow 50.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ACHV +43.04% ICCC +88.76% Spread: +20.9 pp (ICCC Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
ACHV TTM Op. Margin: 0.0% ICCC TTM Op. Margin: 15.2%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ACHV vs ICCC. Trailing 12-month operating profitability (ACHV 0.0% vs ICCC 15.2%) and valuation multiples (ACHV 35.3x vs ICCC N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ACHV (4) vs ICCC (6)
Institutional Metric ACHV ICCC Criterion Row Winner
Market Capitalization Scale $692.8M $97.7M Larger Scale ACHV
Trailing P/E Ratio Valuation 35.3x 56.6x Lower Multiple ACHV
Forward P/E Ratio Valuation 35.3x N/M Lower Multiple ACHV
Revenue Growth (YoY) Growth +0.0% +11.5% Higher Growth ICCC
Operating Margin (TTM) Profitability 0.0% 15.2% Higher Margin ICCC
Net Profit Margin Profitability 0.0% 2.6% Higher Margin ICCC
Return on Equity (ROE) Capital Efficiency -845.0% 2.6% Higher ROE ICCC
52-Week Range Position Momentum 69% ($3โ€“$9) 91% ($5โ€“$12) Stronger Trend ICCC
Beta / 30D Volatility Risk Regime 1.73ฮฒ ยท 62% Vol 0.24ฮฒ ยท 46% Vol Lower Realized Risk ICCC
Unified Institutional Score Composite Signal 56.6 / 100 (HOLD) 43.8 / 100 (HOLD) Higher Composite ACHV

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ACHV vs ICCC Buy Guide
ACHV BREAKOUT
125d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 23rd %ile
IV Regime Compressed (<25th %ile)
Live ACHV Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ICCC UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live ICCC Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ACHV nor ICCC registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.